Retatrutide vs Survodutide: Triple vs Dual Agonist
Here is how these two compounds compare — based on published research, not marketing claims.
Retatrutide
131
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
Survodutide
16388
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
These are the two investigational compounds most likely to reshape weight management after semaglutide and tirzepatide. Retatrutide activates three receptors: GLP-1, GIP, and glucagon. Survodutide activates two: GLP-1 and glucagon. More receptors does not automatically mean better results. This comparison looks at what the Phase 2 data tells us and what questions remain.
Key Differences
| Attribute | Retatrutide | Survodutide |
|---|---|---|
| Evidence Level | Human Trials | Human Trials |
| Category | Triple Agonist (GLP-1/GIP/Glucagon) | Dual Agonist (GLP-1/Glucagon) |
| Human Data | Phase 2 showed up to 24% weight loss at 48 weeks. The highest reported for any investigational compound. Phase 3 ongoing. | Phase 2 showed up to 19% weight loss at 46 weeks. Phase 3 trials underway. |
| Safety Profile | Phase 2 showed GI side effects consistent with the class. Phase 3 in progress. Long-term safety unknown. | Phase 2 showed manageable GI side effects. Phase 3 in progress. |
| Key Limitations | Phase 3 not complete. Triple agonism adds complexity. Long-term effects of simultaneous activation unknown. | Not yet approved. Phase 3 results pending. Glucagon effects on glucose homeostasis need long-term monitoring. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
Retatrutide
Activates three metabolic receptors simultaneously. GLP-1 reduces appetite. GIP enhances insulin sensitivity and fat metabolism. Glucagon increases energy expenditure. Three levers instead of one or two.
Survodutide
Activates GLP-1 for appetite reduction and glucagon for increased energy expenditure and liver fat oxidation. Two complementary metabolic levers.
Retatrutide uses three keys. Survodutide uses two. Both include GLP-1 (appetite) and glucagon (energy burn). Retatrutide adds GIP (insulin and fat metabolism). Whether that third receptor produces meaningfully better outcomes or just adds complexity is the open question.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 16,519 indexed studies. Here are the key findings.
Both L3. Both in Phase 3. Retatrutide showed more weight loss in Phase 2 (24% vs 19%). But Phase 2 results are not guarantees. Neither has regulatory approval. No head-to-head data exists.
For maximum weight loss based on Phase 2 data, retatrutide showed higher numbers.
For liver fat specifically, survodutide's glucagon component has shown particular promise for MASH.
For a simpler mechanism with potentially fewer unknowns, survodutide targets fewer receptors.
For both compounds, Phase 3 results will determine the real-world picture.
Key Limitations
- •Both are in Phase 3. Results pending.
- •No head-to-head trial exists or is planned.
- •Phase 2 weight loss numbers do not predict Phase 3 outcomes.
- •Safety profiles will only be clear after larger, longer trials.
PSI Verdict
SUPPORTED BY EVIDENCE
Retatrutide produced up to 24% weight loss in Phase 2, the highest reported for any investigational compound. Survodutide produced up to 19% weight loss with notable liver fat reduction through glucagon receptor activity.
NOT YET ESTABLISHED
Neither has completed Phase 3 trials. Phase 2 results do not guarantee Phase 3 success. Whether triple agonism is meaningfully superior to dual agonism in humans is unknown.
CONFIDENCE LEVEL
Low-moderate for both. The Phase 2 data is exciting for both compounds. But Phase 2 excitement has failed to translate many times in obesity drug development. Wait for Phase 3.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Retatrutide
"Retatrutide will make Ozempic and Mounjaro obsolete"Plausible but premature
"The triple agonist mechanism is a game-changer"Supported by evidence
"Retatrutide causes a weird tingling skin sensation"Supported by evidence
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
Retatrutide
Phase 2 showed GI side effects consistent with the class. Phase 3 in progress. Long-term safety unknown.
Survodutide
Phase 2 showed manageable GI side effects. Phase 3 in progress.
Both showed manageable GI side effects in Phase 2. Retatrutide's triple agonism introduces more pharmacological variables. Survodutide's dual mechanism is simpler. Neither has long-term safety data.
WHAT THE RESEARCH SUGGESTS
Retatrutide has the more impressive Phase 2 data. Survodutide has the simpler mechanism. Both could be approved. Both could disappoint. The race is far from over.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.